Ann: AstraZeneca to use new ResApp software in clinical study, page-53

From my perspective, this appears to be the first case where another business (AstraZeneca) has enlisted Resapp's algorithm as a tool or feature within another project.

All of our past trial / test / pilot projects have been designed to test some aspect of ResappDx — efficacy or commerciality — prior to adopting it as an end product.

This AstraZeneca project is based on acceptance that the algorithm works, and can be used as an integral part of a larger process or product.

So when Tony Keating says that this is "significant validation", he's not joking. This represents a major shift in Resapp's place within the industry.